236 related articles for article (PubMed ID: 29299639)
1. B7-H3 in tumors: friend or foe for tumor immunity?
Li G; Quan Y; Che F; Wang L
Cancer Chemother Pharmacol; 2018 Feb; 81(2):245-253. PubMed ID: 29299639
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
[TBL] [Abstract][Full Text] [Related]
3. B7-H3-mediated tumor immunology: Friend or foe?
Wang L; Kang FB; Shan BE
Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
Lee YH; Martin-Orozco N; Zheng P; Li J; Zhang P; Tan H; Park HJ; Jeong M; Chang SH; Kim BS; Xiong W; Zang W; Guo L; Liu Y; Dong ZJ; Overwijk WW; Hwu P; Yi Q; Kwak L; Yang Z; Mak TW; Li W; Radvanyi LG; Ni L; Liu D; Dong C
Cell Res; 2017 Aug; 27(8):1034-1045. PubMed ID: 28685773
[TBL] [Abstract][Full Text] [Related]
5. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses.
Hashiguchi M; Kobori H; Ritprajak P; Kamimura Y; Kozono H; Azuma M
Proc Natl Acad Sci U S A; 2008 Jul; 105(30):10495-500. PubMed ID: 18650384
[TBL] [Abstract][Full Text] [Related]
6. [Research Progress on Co-stimulating Molecule B7-H3 in Hematological Malignancies].
Zhang W; Wang J; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1758-62. PubMed ID: 26708906
[TBL] [Abstract][Full Text] [Related]
7. Murine b7-h3 is a co-stimulatory molecule for T cell activation.
Yan R; Yang S; Gu A; Zhan F; He C; Qin C; Zhang X; Feng P
Monoclon Antib Immunodiagn Immunother; 2013 Dec; 32(6):395-8. PubMed ID: 24328742
[TBL] [Abstract][Full Text] [Related]
8. B7-h3 and its role in antitumor immunity.
Loos M; Hedderich DM; Friess H; Kleeff J
Clin Dev Immunol; 2010; 2010():683875. PubMed ID: 21127709
[TBL] [Abstract][Full Text] [Related]
9. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction.
Leitner J; Klauser C; Pickl WF; Stöckl J; Majdic O; Bardet AF; Kreil DP; Dong C; Yamazaki T; Zlabinger G; Pfistershammer K; Steinberger P
Eur J Immunol; 2009 Jul; 39(7):1754-64. PubMed ID: 19544488
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors.
Xu H; Cheung IY; Guo HF; Cheung NK
Cancer Res; 2009 Aug; 69(15):6275-81. PubMed ID: 19584290
[TBL] [Abstract][Full Text] [Related]
11. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
[TBL] [Abstract][Full Text] [Related]
12. B7-H3 in Cancer - Beyond Immune Regulation.
Flem-Karlsen K; Fodstad Ø; Tan M; Nunes-Xavier CE
Trends Cancer; 2018 Jun; 4(6):401-404. PubMed ID: 29860983
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
14. Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.
Calabrò L; Sigalotti L; Fonsatti E; Bertocci E; Di Giacomo AM; Danielli R; Cutaia O; Colizzi F; Covre A; Mutti L; Natali PG; Maio M
J Cell Physiol; 2011 Oct; 226(10):2595-600. PubMed ID: 21792917
[TBL] [Abstract][Full Text] [Related]
15. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer.
Zhang P; Yu S; Li H; Liu C; Li J; Lin W; Gao A; Wang L; Gao W; Sun Y
FEBS Lett; 2015 Aug; 589(17):2248-56. PubMed ID: 26149216
[TBL] [Abstract][Full Text] [Related]
16. [Identification and characterization of monoclonal antibody Y4F11 against human B7-H3].
Shi Z; Hu Y; Chen H; Fu F; Zhang X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Oct; 32(10):1402-1406. PubMed ID: 27667469
[TBL] [Abstract][Full Text] [Related]
17. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
18. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.
Mao Y; Li W; Chen K; Xie Y; Liu Q; Yao M; Duan W; Zhou X; Liang R; Tao M
Oncotarget; 2015 Feb; 6(5):3452-61. PubMed ID: 25609202
[TBL] [Abstract][Full Text] [Related]
19. Negative roles of B7-H3 and B7-H4 in the microenvironment of cervical cancer.
Han S; Wang Y; Shi X; Zong L; Liu L; Zhang J; Qian Q; Jin J; Ma Y; Cui B; Yang X; Kong B; Zhang Y
Exp Cell Res; 2018 Oct; 371(1):222-230. PubMed ID: 30099052
[TBL] [Abstract][Full Text] [Related]
20. B7-H3 on breast cancer cell MCF7 inhibits IFN-γ release from tumour-infiltrating T cells.
Shao L; Yu Q; Xia R; Zhang J; Gu S; Yu D; Zhuang Z
Pathol Res Pract; 2021 Aug; 224():153461. PubMed ID: 34265738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
